Rhythm Pharmaceuticals, Inc.
Clinical trials sponsored by Rhythm Pharmaceuticals, Inc., explained in plain language.
Biopharmaceutical company developing therapies for rare genetic obesity disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to curb hunger in Prader-Willi syndrome Results expected Oct 2026 (estimated) May already have reported ↗
- Hope for hypothalamic obesity: daily shot targets weight and hunger Results expected Mar 2027 (estimated) May already have reported ↗ 🚀 Make-or-break
-
Promising drug targets obesity caused by brain damage
Disease control OngoingThis study tests a daily injection called setmelanotide to help people aged 4 and older who gained weight after a brain injury (hypothalamic obesity). The goal is to see if it reduces body weight, hunger, and improves quality of life over 52 weeks. Half of the 143 participants wi…
Phase 3 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug aims to curb hunger in Prader-Willi syndrome
Disease control OngoingThis phase 2 trial tests setmelanotide (Imcivree), a daily injection, in 18 people aged 6 to 65 with Prader-Willi syndrome who have obesity. The study will check if the drug is safe and helps reduce body weight and hunger over 52 weeks.
Phase 2 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New hope for hypothalamic obesity: Long-Term drug trial launches
Disease control By invitation onlyThis study looks at the long-term safety and effects of a drug called bivamelagon in people with hypothalamic obesity, a condition where the brain's hunger control is damaged. About 25 participants who completed a previous study will take the drug for up to 2 years. Researchers w…
Phase 2 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC